- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產品
- 聯(lián)系我們
Maraviroc
別名: UK-427857 中文名稱：馬拉維若
Maraviroc是一種CCR5拮抗劑，作用于MIP-1α，MIP-1β和RANTES，無細胞試驗中IC50分別為3.3 nM，7.2 nM和5.2 nM。Maraviroc可應用于治療HIV感染。
Maraviroc Chemical Structure
CAS: 376348-65-1
產品質控
批次：
純度：
99.99%
99.99
常與Maraviroc一起在實驗中被使用的化合物
Maraviroc和Pembrolizumab在轉移性結直腸癌的1期試驗中顯示出陽性毒性模式。
在RET細胞-細胞融合測定中，Maraviroc和Leronlimab(PRO-140)共同抑制HIV-1JR-FL包膜介導的膜融合。
Murga JD, et al. Antimicrob Agents Chemother. 2006 Oct;50(10):3289-96.
Maraviroc和Etravirine可用于挽救核苷逆轉錄酶抑制劑(NRTI)完全耐藥的患者。
Vallabhaneni S, et al. J Int AIDS Soc. 2013 Jun 3;16(1):18449.
Maraviroc和Vicriviroc可減少免疫功能正常小鼠的前列腺癌細胞向骨骼、大腦和內臟的轉移。
Maraviroc和Tenofovir對孕激素受體B(PR-B)的激活具有背景特異性影響。
Enfield K, et al. Biochem Biophys Res Commun. 2020 Dec 17;533(4):1027-1033.
Maraviroc相關產品
| 相關靶點 | CCR1 CCR2 CCR3 CCR4 CCR5 CCR8 CCL | 點擊展開 |
|---|---|---|
| 相關產品 | Cenicriviroc Vicriviroc Malate Adaptavir (DAPTA) ZK756326 2HCl SB-297006 INCB3344 RS102895 Vicriviroc maleate AZD2098 | 點擊展開 |
| 相關化合物庫 | 抗感染化合物庫 抗生素化合物庫 抗病毒化合物庫 抗寄生蟲藥物庫 腸道微生物代謝物庫 | 點擊展開 |
相關信號通路圖
細胞實驗數據示例
| 細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
|---|---|---|---|---|---|
| TZM-bl | Function assay | 48 hrs | Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 YU2-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay, IC50 = 0.00043 μM. | 24563723 | |
| TZM-bl | Function assay | 48 hrs | Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 MGC26-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay, IC50 = 0.00037 μM. | 24563723 | |
| TZM-bl | Function assay | 3 days | Inhibition of CCR5 in human TZM-bl cells infected with HIV1 Bal R5 assessed as antiviral activity by measuring reduction in viral infection pre-incubated with cells followed by viral infection measured after 3 days by luciferase reporter gene assay, IC50 = 0.0002 μM. | 28082070 | |
| HeLa-P4 | Function assay | 20 hrs | Antagonist activity at CCR5 receptor expressed in HeLa-P4 cells co-expressing CD4 assessed as inhibition of infusion to HIV gp120 expressed in CHO-tat10 cells after 20 hrs by cell-cell fusion assay, IC50 = 0.0002 μM. | 21128663 | |
| PM1 | Antiviral assay | 5 days | Antiviral activity against CCR5-dependent HIV1 Ba-L infected in human PM1 cells assessed as reduction in virus infection measured after 5 days by luciferase reporter gene assay, IC50 = 0.001 μM. | 30234300 | |
| SupT1 | Antiviral assay | 48 hrs | Antiviral activity against HIV-1 infected in human SupT1 cells assessed as inhibition of viral infectivity after 48 hrs by luciferase reporter gene assay, IC50 = 0.0011 μM. | 24316669 | |
| TZM-bl | Function assay | 48 hrs | Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 92RW-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay, IC50 = 0.0013 μM. | 24563723 | |
| CHO | Function assay | 2 hrs | Displacement of [128I]RANTES from human CCR5 receptor coexpressed with Galphai6 in CHO cells after 2 hrs by scintillation counting, IC50 = 0.0014 μM. | 20137937 | |
| TZM-bl | Function assay | 48 hrs | Antagonist activity against CCR5 receptor in human TZM-bl cells assessed as inhibition of HIV-1 JR-FL-induced cell-cell fusion between viral envelope protein expressing human HEK293 cells to TZM-bl cells after 48 hrs by luciferase reporter gene assay, IC50 = 0.0016 μM. | 24563723 | |
| HOS | Antiviral assay | 5 days | Antiviral activity against CCR5-dependent HIV1 Ba-L infected in human HOS cells assessed as reduction in virus infection measured after 5 days by luciferase reporter gene assay, IC50 = 0.0019 μM. | 30234300 | |
| MOLT4 | Function assay | 15 mins | Antagonist activity at CCR5 in Gqi5 transfected human MOLT4 cells assessed as inhibition of RANTES-stimulated Ca2+ influx preincubated for 15 mins followed by DAMGO challenge, IC50 = 0.0022 μM. | 23682308 | |
| JC53-BL | Antiviral assay | 3 days | Antiviral activity against CCR5-tropic recombinant HIV1 NLBal virus infected in JC53-BL cells assessed as inhibition of viral replication after 3 days by luciferase reporter gene assay, IC50 = 0.0028 μM. | 20137937 | |
| JC53-BL | Antiviral assay | 3 days | Antiviral activity against HIV1 NL4-3 infected in human JC53-BL cells assessed as luciferase activity after 3 days post infection, IC50 = 0.003 μM. | 20417098 | |
| HOS | Antiviral assay | 5 days | Antiviral activity against CCR5-dependent HIV1 SF162 infected in human HOS cells assessed as reduction in virus infection measured after 5 days by luciferase reporter gene assay, IC50 = 0.0047 μM. | 30234300 | |
| NIH/3T3 | Function assay | 1 hr | Displacement of [125I]-RANTES from CCR5 in mouse NIH/3T3 cells after 1 hr, IC50 = 0.0052 μM. | 29425816 | |
| SupT1 | Antiviral assay | 48 hrs | Antiviral activity against HIV1 infected in human SupT1 cells exposed to supernatant from HIV1 infected human 293T cells incubated for 48 hrs by firefly luciferase assay based single-cycle HIV1 replication assay, IC50 = 0.0055 μM. | 25638498 | |
| TZM-bl | Antiviral assay | 48 hrs | Antiviral activity against CCR5-dependent HIV1 SF162 infected in human TZM-bl cells assessed as reduction in virus infection measured after 48 hrs post infection by luciferase reporter gene assay, IC50 = 0.0067 μM. | 30234300 | |
| HEK293 | Function assay | 10 mins | Antagonist activity at CCR5 (unknown origin) expressed in HEK293 cells co-expressing Galpha16 assessed as inhibition of RANTES-induced calcium flux preincubated for 10 mins followed by RANTES addition by fluo-4AM-based fluorescence assay, IC50 = 0.008 μM. | 30234300 | |
| CHO | Function assay | 10 mins | Antagonist activity against CCR5 (unknown origin) expressed in CHO cells co-expressing Galpha16 incubated for 10 mins assessed as inhibition of RANTES-induced calcium mobilization, IC50 = 0.0131 μM. | 25638498 | |
| CHO | Function assay | 10 mins | Inhibition of CCR5 (unknown origin) expressed in CHO cells assessed as inhibition of RANTES-induced intracellular Ca2+ mobilization after 10 mins by Fluo-4 AM staining-based fluorescence assay, IC50 = 0.02543 μM. | 24316669 | |
| HEK293 | Function assay | 1.5 mins | Inhibition of human MATE1-mediated ASP+ uptake expressed in HEK293 cells after 1.5 mins by fluorescence assay, IC50 = 17.3 μM. | 23241029 | |
| HeLa-P4 | Function assay | Antagonist activity at human recombinant CCR5 expressed in human HeLa-P4 cells assessed as inhibition of human HeLa-P4 cells binding to HIV1 gp160 expressing CHO cells by cell-cell fusion assay, IC50 = 0.0002 μM. | 19171484 | ||
| PM1 | Antiviral assay | Antiviral activity against HIV1 Bal infected in human PM1 cells assessed as inhibition of viral replication, IC90 = 0.0007 μM. | 19171484 | ||
| HOS | Antiviral assay | Antiviral activity against HIV1 Ba-L infected in HOS cells assessed as inhibition of viral infection, IC50 = 0.002 μM. | 19664920 | ||
| A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
| NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 29435139 | ||
| Rh30 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 29435139 | ||
| RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
| NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 29435139 | ||
| SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 29435139 | ||
| SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 29435139 | ||
| Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 29435139 | ||
| 點擊查看更多細胞系數據 | |||||
生物活性
| 產品描述 | Maraviroc是一種CCR5拮抗劑，作用于MIP-1α，MIP-1β和RANTES，無細胞試驗中IC50分別為3.3 nM，7.2 nM和5.2 nM。Maraviroc可應用于治療HIV感染。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 靶點 |
|
| 體外研究(In Vitro) | ||||
| 體外研究活性 | Maraviroc 抑制MIP-1β刺激的γ-S-GTP 結合到HEK-293細胞膜上, 說明 Maraviroc 可抑制GDP-GTP 在CCR5/G 蛋白復合體上交換的趨化因子依賴性刺激。Maraviroc 也抑制趨化因子誘導的細胞內鈣重新分配的下游事件，作用于 MIP-1β, MIP-1α 和RANTES時，IC50s 為 7 到 30 nM。在相同實驗中, Maraviroc 即使?jié)舛雀哌_10 μM，也不會觸發(fā)細胞內鈣釋放，說明Maraviroc 缺乏 CCR5興奮劑活性。與此相應地, Maraviroc也不能誘導CCR5內化。Maraviroc 低納摩爾濃度時，也有效作用于 HIV-1 Ba-L。 Maraviroc 抑制所有 200種假型病毒，平均IC90為13.7 nM。[1] 在濃度高達其IC50的1000倍時，Maraviroc對其他chemokine receptors (CCR1, 2, 3, 4, 7, 8; CXCR1, 2) 沒有相關臨床程度的抑制作用[3]. |
|||
|---|---|---|---|---|
| 激酶實驗 | 趨化因子與 CCR5結合的抑制作用 | |||
| 使用穩(wěn)定表達受體或膜及其制品的昆蟲HEK-293細胞測量125I-標記的 MIP-1α, MIP-1β,和 RANTES 與CCR5結合情況。細胞按2 × 106 個細胞/ml的密度再懸浮在結合buffer (50 mM HEPES 含1 mM CaCl2, 5 mM MgCl2, 和 0.5%牛血清蛋白[BSA]，調節(jié)pH為 7.4) 中。為了制備膜，PBS沖洗的細胞再懸浮在 裂解 buffer (20 mM HEPES, 1 mM CaCl2, 1 片 COMPLETE /50 mL, pH 7.4)中，然后在Polytron 手持勻漿器中攪勻, 在40,000× g下超速離心30分鐘，再懸浮在 結合 buffer中，蛋白濃度為0.25 mg/mL (96-孔板的每孔中含 12.5 μg 膜蛋白)。制備125I-放射性標記的 MIP-1α, MIP-1β, 和 RANTES ，在 結合 buffer中稀釋，終濃度為400 pM。每孔加入Maraviroc 稀釋液，終體積為100 μL, 實驗板溫育1小時, 通過預阻斷和沖洗的 Unifilter 板過濾，計數，烘干過夜。 | ||||
| 細胞實驗 | 細胞系 | PHA刺激的PBMC或PM-1細胞 | ||
| 濃度 | 0-1 μM | |||
| 孵育時間 | 5天或7天 | |||
| 方法 | 在24孔組織培養(yǎng)板上進行藥物敏感性試驗。在DMSO中制備重復的8點連續(xù)稀釋Maraviroc，實驗中DMSO終濃度為 0.1% (vol/vol)。PHA刺激的PBMC或PM-1細胞感染細胞，在37oC下進行1小時。細胞隨后稀釋一次，3.6 × 105 PBMC 或2.0 × 105 PM-1細胞加到含稀釋 Maraviroc的每孔中。實驗板在37oC下在含5% CO2 (vol/vol) 環(huán)境下溫育5天（實驗室適應株）或7天（原始分離株）。所有實驗中含Saquinavir (一種 HIV-1 蛋白酶抑制劑) 和RANTES。 |
|||
| 實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
| Western blot | cleaved caspase-3 / cleaved caspase-9 / cleaved PARP / XIAP / Survivin / c-IAP1 / c-IAP2 / Bax / Bad / Bcl2 / Bcl-xl |
|
28469959 | |
| 體內研究(In Vivo) | ||
| 體內研究活性 | Maraviroc 作用于大鼠的半衰期為 0.9小時，作用于犬類的半衰期為2.3小時。 隨后Maraviroc按2 mg/kg劑量口服給藥犬類，1.5小時后達到 Cmax(256 ng/ml)，生物有效性為40%。Maraviroc作用于大鼠，大約 30% 給藥劑量從腸道吸收。[1]雌性RAG-hu小鼠陰道內部加入 Maraviroc凝膠后，再陰道注入HIV-1 1小時。Maraviroc 凝膠處理的小鼠完全免受HIV-1 感染，而安慰劑處理的小鼠則全部感染。說明Maraviroc 完全保護小鼠免受 HIV-1 感染。在安慰劑處理的病毒感染小鼠內，CD4 T細胞明顯下降，而Maraviroc 凝膠處理小鼠中水平穩(wěn)定。[2] |
|
|---|---|---|
| 動物實驗 | Animal Models | 人性化的 BALB/c-Rag2?/?γc?/?和BALB/c-Rag1?/?γc?/? (RAG-hu)小鼠 |
| Dosages | ~64 μg | |
| Administration | 25μL凝膠配方小心地加到小鼠的陰道穹窿中。 | |
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04966429 | Recruiting | Post Stroke Cognitive Impairment |
Tel-Aviv Sourasky Medical Center|Hadassah Medical Organization|Soroka University Medical Center |
May 1 2021 | Phase 2 |
| NCT04710199 | Completed | Virus Diseases |
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla |
February 23 2021 | Phase 2 |
| NCT02881762 | Completed | Hepatitis C|Human Immunodeficiency Virus |
University of Maryland Baltimore|ViiV Healthcare |
June 1 2017 | Phase 4 |
| NCT02778204 | Completed | HIV Infections |
National Institute of Allergy and Infectious Diseases (NIAID)|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|ViiV Healthcare|GlaxoSmithKline |
June 5 2017 | Phase 1 |
| NCT02741323 | Completed | HIV Infections|Kidney Diseases |
National Institute of Allergy and Infectious Diseases (NIAID) |
January 1 2017 | Phase 2 |
化學信息&溶解度
| 分子量 | 513.67 | 分子式 | C29H41F2N5O |
| CAS號 | 376348-65-1 | SDF | Download Maraviroc SDF |
| Smiles | CC1=NN=C(N1C2CC3CCC(C2)N3CCC(C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C | ||
| 儲存條件(自收到貨起) | |||
|
體外溶解度 |
DMSO : 100 mg/mL ( (194.67 mM) ；DMSO吸濕會降低化合物溶解度，請使用新開封DMSO) Ethanol : 100 mg/mL (194.67 mM) Water : Insoluble |
摩爾濃度計算器 |
|
體內溶解度 現配現用，請按從左到右的順序依次添加，澄清后再加入下一溶劑 |
動物體內配方計算器 | ||||
實驗計算
動物體內配方計算器（澄清溶液）
第一步：請輸入基本實驗信息（考慮到實驗過程中的損耗，建議多配一只動物的藥量）
mg/kg
g
μL
只
第二步：請輸入動物體內配方組成（配方適用于不溶于水的藥物；不同批次藥物配方比例不同，請聯(lián)系Selleck為您提供正確的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
計算結果：
工作液濃度： mg/ml；
DMSO母液配制方法： mg 藥物溶于μL DMSO溶液（母液濃度mg/mL，注：如該濃度超過該批次藥物DMSO溶解度，請先聯(lián)系Selleck）；
體內配方配制方法：取μL DMSO母液，加入μL PEG300，混勻澄清后加入μL Tween 80，混勻澄清后加入μL ddH2O，混勻澄清。
體內配方配制方法：取μL DMSO母液，加入μL Corn oil，混勻澄清。
注意：1. 首先保證母液是澄清的；
2.一定要按照順序依次將溶劑加入，進行下一步操作之前必須保證上一步操作得到的是澄清的溶液，可采用渦旋、超聲或水浴加熱等物理方法助溶。
技術支持
在訂購、運輸、儲存和使用我們的產品的任何階段，您遇到的任何問題，均可以通過撥打我們的熱線電話400-668-6834，或者技術支持郵箱tech@selleck.cn，直接聯(lián)系到我們。我們會在24小時內盡快聯(lián)系您。
如果有其他問題，請給我們留言。
* 必填項
常見問題及建議解決方法
問題 1:
What’s the vehicle do you recommend to dissolve the compound for in vivo experiments?
回答：
S2003 Maraviroc can be dissolved in 5% DMSO/castor oil at 62 mg/ml as suspension for oral administration. As to a clear solution for injection, following three vehicles at 10mg/ml will help: 1. 2% DMSO/castor oil; 2. 2%DMSO/sunflower oil; 3. 2%DMSO/30%PEG 300/ddH2O.
Tags: buy Maraviroc | Maraviroc ic50 | Maraviroc price | Maraviroc cost | Maraviroc solubility dmso | Maraviroc purchase | Maraviroc manufacturer | Maraviroc research buy | Maraviroc order | Maraviroc mouse | Maraviroc chemical structure | Maraviroc mw | Maraviroc molecular weight | Maraviroc datasheet | Maraviroc supplier | Maraviroc in vitro | Maraviroc cell line | Maraviroc concentration | Maraviroc nmr
